Phase II Study Evaluating the Addition of Cetuximab to the Concurrent Delivery of Weekly Carboplatin, Paclitaxel, and Daily Radiotherapy for Patients With Locally Advanced Squamous Cell Carcinomas of the Head and Neck
Mohan Suntharalingam(University of Maryland, Baltimore), Kevin J. Cullen(University of Maryland, Baltimore), R. Taylor(University of Oxford), Young Kwok(University of Maryland, Baltimore), Ann B. Zimrin(University of Maryland, Baltimore), Jeffrey S. Wolf(University of Maryland, Baltimore), Robert A. Ord(University of Maryland, Baltimore), Olga Goloubeva(University of Maryland, Baltimore), Arti Parekh(University of Maryland, Baltimore), Scott E. Strome(Northwestern Medicine Lake Forest Hospital)
Cited by 36
Related Papers
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
|Nature Medicine|2002|5.1k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target
|Proceedings of the National Academy of Sciences|2004|767
Erratum: Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
|Nature Medicine|2002|548